Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Service delivery challenges in HIV care during the first year of the COVID-19 pandemic: results from a site assessment survey across the global IeDEA consortium.
Brazier E, Ajeh R, Maruri F, Musick B, Freeman A, Wester CW, Lee MP, Shamu T, Crabtree Ramírez B, d'Almeida M, Wools-Kaloustian K, Kumarasamy N, Althoff KN, Twizere C, Grinsztejn B, Tanser F, Messou E, Byakwaga H, Duda SN, Nash D; International epidemiology Databases to Evaluate AIDS. Brazier E, et al. J Int AIDS Soc. 2022 Dec;25(12):e26036. doi: 10.1002/jia2.26036. J Int AIDS Soc. 2022. PMID: 36504431 Free PMC article.
A Heavy Burden: Preexisting Physical and Psychiatric Comorbidities and Differential Increases Among Male and Female Participants After Initiating Antiretroviral Therapy in the HIV Outpatient Study, 2008-2018.
Tedaldi E, Armon C, Li J, Mahnken J, Simoncini G, Palella F, Carlson K, Buchacz K; HIV Outpatient Study (HOPS) Investigators. Tedaldi E, et al. AIDS Res Hum Retroviruses. 2022 Jul;38(7):519-529. doi: 10.1089/AID.2021.0178. Epub 2022 May 18. AIDS Res Hum Retroviruses. 2022. PMID: 35451335
Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group. Lancet Infect Dis. 2022 May;22(5):622-635. doi: 10.1016/S1473-3099(21)00751-9. Epub 2021 Dec 23. Lancet Infect Dis. 2022. PMID: 34953520 Free PMC article. Clinical Trial.
Corticosteroid treatment in COVID-19 modulates host inflammatory responses and transcriptional signatures of immune dysregulation.
Pinski AN, Steffen TL, Zulu MZ, George SL, Dickson A, Tifrea D, Maroney KJ, Tedeschi N, Zhang Y, Scheuermann RH, Pinto AK, Brien JD, Messaoudi I. Pinski AN, et al. Among authors: maroney kj. J Leukoc Biol. 2021 Dec;110(6):1225-1239. doi: 10.1002/JLB.4COVA0121-084RR. Epub 2021 Nov 3. J Leukoc Biol. 2021. PMID: 34730254 Free PMC article.
19 results